CNS Drug Discovery Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on CNS Drug Discovery Market 

5.1. COVID-19 Landscape: CNS Drug Discovery Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global CNS Drug Discovery Market, By Drug Type

8.1. CNS Drug Discovery Market, by Drug Type

8.1.1. Small Molecules

8.1.1.1. Market Revenue and Forecast

8.1.2. Biologics

8.1.2.1. Market Revenue and Forecast

8.1.3. Gene Therapies

8.1.3.1. Market Revenue and Forecast

8.1.4. Cell Therapies

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global CNS Drug Discovery Market, By Indication

9.1. CNS Drug Discovery Market, by Indication

9.1.1. Alzheimer’s Disease

9.1.1.1. Market Revenue and Forecast

9.1.2. Parkinson’s Disease

9.1.2.1. Market Revenue and Forecast

9.1.3. Epilepsy

9.1.3.1. Market Revenue and Forecast

9.1.4. Multiple Sclerosis

9.1.4.1. Market Revenue and Forecast

9.1.5. Schizophrenia

9.1.5.1. Market Revenue and Forecast

9.1.6. Depression and Anxiety Disorders

9.1.6.1. Market Revenue and Forecast

Chapter 10. Global CNS Drug Discovery Market, By Discovery Stage 

10.1. CNS Drug Discovery Market, by Discovery Stage

10.1.1. Target Identification and Validation

10.1.1.1. Market Revenue and Forecast

10.1.2. Lead Identification

10.1.2.1. Market Revenue and Forecast

10.1.3. Lead Optimization

10.1.3.1. Market Revenue and Forecast

10.1.4. Preclinical Development

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global CNS Drug Discovery Market, By Technology

11.1. CNS Drug Discovery Market, by Technology

11.1.1. High Throughput Screening (HTS)

11.1.1.1. Market Revenue and Forecast

11.1.2. Genomics and Proteomics

11.1.2.1. Market Revenue and Forecast

11.1.3. AI-enabled Drug Discovery

11.1.3.1. Market Revenue and Forecast

11.1.4. Biomarker-based Discovery

11.1.4.1. Market Revenue and Forecast

11.1.5. CRISPR and Gene Editing Platforms

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global CNS Drug Discovery Market, By End Use

12.1. CNS Drug Discovery Market, by End Use

12.1.1. Pharmaceutical Companies

12.1.1.1. Market Revenue and Forecast

12.1.2. Biotechnology Companies

12.1.2.1. Market Revenue and Forecast

12.1.3. Academic and Research Institutes

12.1.3.1. Market Revenue and Forecast

12.1.4. Contract Research Organizations (CROs)

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global CNS Drug Discovery Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Drug Type

13.1.2. Market Revenue and Forecast, by Indication

13.1.3. Market Revenue and Forecast, by Discovery Stage

13.1.4. Market Revenue and Forecast, by Technology

13.1.5. Market Revenue and Forecast, by End Use

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Drug Type

13.1.6.2. Market Revenue and Forecast, by Indication

13.1.6.3. Market Revenue and Forecast, by Discovery Stage

13.1.6.4. Market Revenue and Forecast, by Technology

13.1.6.5. Market Revenue and Forecast, by End Use  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Drug Type

13.1.7.2. Market Revenue and Forecast, by Indication

13.1.7.3. Market Revenue and Forecast, by Discovery Stage

13.1.7.4. Market Revenue and Forecast, by Technology

13.1.7.5. Market Revenue and Forecast, by End Use

13.2. Europe

13.2.1. Market Revenue and Forecast, by Drug Type

13.2.2. Market Revenue and Forecast, by Indication

13.2.3. Market Revenue and Forecast, by Discovery Stage

13.2.4. Market Revenue and Forecast, by Technology  

13.2.5. Market Revenue and Forecast, by End Use  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Drug Type

13.2.6.2. Market Revenue and Forecast, by Indication

13.2.6.3. Market Revenue and Forecast, by Discovery Stage

13.2.7. Market Revenue and Forecast, by Technology  

13.2.8. Market Revenue and Forecast, by End Use  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Drug Type

13.2.9.2. Market Revenue and Forecast, by Indication

13.2.9.3. Market Revenue and Forecast, by Discovery Stage

13.2.10. Market Revenue and Forecast, by Technology

13.2.11. Market Revenue and Forecast, by End Use

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Drug Type

13.2.12.2. Market Revenue and Forecast, by Indication

13.2.12.3. Market Revenue and Forecast, by Discovery Stage

13.2.12.4. Market Revenue and Forecast, by Technology

13.2.13. Market Revenue and Forecast, by End Use

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Drug Type

13.2.14.2. Market Revenue and Forecast, by Indication

13.2.14.3. Market Revenue and Forecast, by Discovery Stage

13.2.14.4. Market Revenue and Forecast, by Technology

13.2.15. Market Revenue and Forecast, by End Use

13.3. APAC

13.3.1. Market Revenue and Forecast, by Drug Type

13.3.2. Market Revenue and Forecast, by Indication

13.3.3. Market Revenue and Forecast, by Discovery Stage

13.3.4. Market Revenue and Forecast, by Technology

13.3.5. Market Revenue and Forecast, by End Use

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Drug Type

13.3.6.2. Market Revenue and Forecast, by Indication

13.3.6.3. Market Revenue and Forecast, by Discovery Stage

13.3.6.4. Market Revenue and Forecast, by Technology

13.3.7. Market Revenue and Forecast, by End Use

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Drug Type

13.3.8.2. Market Revenue and Forecast, by Indication

13.3.8.3. Market Revenue and Forecast, by Discovery Stage

13.3.8.4. Market Revenue and Forecast, by Technology

13.3.9. Market Revenue and Forecast, by End Use

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Drug Type

13.3.10.2. Market Revenue and Forecast, by Indication

13.3.10.3. Market Revenue and Forecast, by Discovery Stage

13.3.10.4. Market Revenue and Forecast, by Technology

13.3.10.5. Market Revenue and Forecast, by End Use

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Drug Type

13.3.11.2. Market Revenue and Forecast, by Indication

13.3.11.3. Market Revenue and Forecast, by Discovery Stage

13.3.11.4. Market Revenue and Forecast, by Technology

13.3.11.5. Market Revenue and Forecast, by End Use

13.4. MEA

13.4.1. Market Revenue and Forecast, by Drug Type

13.4.2. Market Revenue and Forecast, by Indication

13.4.3. Market Revenue and Forecast, by Discovery Stage

13.4.4. Market Revenue and Forecast, by Technology

13.4.5. Market Revenue and Forecast, by End Use

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Drug Type

13.4.6.2. Market Revenue and Forecast, by Indication

13.4.6.3. Market Revenue and Forecast, by Discovery Stage

13.4.6.4. Market Revenue and Forecast, by Technology

13.4.7. Market Revenue and Forecast, by End Use

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Drug Type

13.4.8.2. Market Revenue and Forecast, by Indication

13.4.8.3. Market Revenue and Forecast, by Discovery Stage

13.4.8.4. Market Revenue and Forecast, by Technology

13.4.9. Market Revenue and Forecast, by End Use

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Drug Type

13.4.10.2. Market Revenue and Forecast, by Indication

13.4.10.3. Market Revenue and Forecast, by Discovery Stage

13.4.10.4. Market Revenue and Forecast, by Technology

13.4.10.5. Market Revenue and Forecast, by End Use

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Drug Type

13.4.11.2. Market Revenue and Forecast, by Indication

13.4.11.3. Market Revenue and Forecast, by Discovery Stage

13.4.11.4. Market Revenue and Forecast, by Technology

13.4.11.5. Market Revenue and Forecast, by End Use

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Drug Type

13.5.2. Market Revenue and Forecast, by Indication

13.5.3. Market Revenue and Forecast, by Discovery Stage

13.5.4. Market Revenue and Forecast, by Technology

13.5.5. Market Revenue and Forecast, by End Use

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Drug Type

13.5.6.2. Market Revenue and Forecast, by Indication

13.5.6.3. Market Revenue and Forecast, by Discovery Stage

13.5.6.4. Market Revenue and Forecast, by Technology

13.5.7. Market Revenue and Forecast, by End Use

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Drug Type

13.5.8.2. Market Revenue and Forecast, by Indication

13.5.8.3. Market Revenue and Forecast, by Discovery Stage

13.5.8.4. Market Revenue and Forecast, by Technology

13.5.8.5. Market Revenue and Forecast, by End Use

Chapter 14. Company Profiles

14.1. Eli Lilly and Company

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Roche

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Novartis

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Pfizer

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. AbbVie

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Biogen

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Bristol Myers Squibb

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Johnson & Johnson Innovative Medicine

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Otsuka Pharmaceutical

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Takeda Pharmaceutical

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms